About
About Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
Visit company website
5 years, 5 months ago
Hua Medicine (Shanghai) Ltd is currently in a long term downtrend where the price is trading 13.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 15.8% to $-220M since the same quarter in the previous year.
Finally, its free cash flow grew by 188.7% to $73M since the same quarter in the previous year.
Based on the above factors, Hua Medicine (Shanghai) Ltd gets an overall score of 2/5.